期刊文献+

比索洛尔片在健康人体内的药动学和生物等效性 被引量:1

Pharmacokinetics and bioequivalence of bisoprolol tablets in healthy volunteers
原文传递
导出
摘要 目的比较2种进口比索洛尔片剂在健康人体的药动学及生物等效性。方法24例健康男性受试者随机交叉口服比索洛尔受试制剂和参比制剂5mg后,采用液相色谱-串联质谱(LC-MS/MS)法测定血浆中比索洛尔的浓度,经DAS2.0软件计算药动学参数,用方差分析和双单侧t检验评价2种制剂的生物等效性。结果健康受试者口服比索洛尔受试制剂和参比制剂5mg后,血浆中比索洛尔的ρmax、tmax、AUC(0~t)、AUC(0~∞)和t1/2分别为(18±s3)和(18.0±2.9)μg·L-1;(2.2±1.2)和(2.5±1.6)h;(266±48)和(263±39)μg·h·L-1;(276±50)和(274±39)μg·h·L-1;(9.0±1.3)和(9.2±1.0)h。以AUC(0~t)计算,受试制剂的相对生物利用度平均为100.3%,2种制剂各主要药动学参数经双单侧t检验及90%置信区间法检验,差异无显著意义(P>0.05)。结论2种比索洛尔片剂在体内具有生物等效性。 AIM To evaluate the pharmacokinetics and bioequivalence of two imported bisoprolol tablets in healthy volunteers. METHODS Twenty-four healthy male volunteers were cross alternative randomly administered a single dose of 5 mg of test and reference tablets. The bisoprolol concentrations in plasma were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) , and the pharmacokinetic parameters and bioequivalence of the tablets were analyzed through DAS 2.0 software. RESULTS After taking 5 mg of single dose of bisoprolol, the pharmacokinetic parameters of test and reference tabletsin plasma were asfollows: pmax (18 + s 3) vs (18.0 ± 2.9) μg'L^-1; tmax(2.2 ± 1.2) vs (2.5 ± 1.6) h; AUC(o-t) (266 ± 48) vs (263 ±39) μg·h·L^-1; AUC(0-∞) (276 ± 50) vs (274 ± 39) μg·h·L^-1; t1/2(9.0 ± 1.3) vs (9.2 ±1.0) h. The relative bioavailability of the test formulation was 100.3%. There were no significant differences in pmax tmax,AU C (o-t), and AUC(o-∞) between the two preparations (P 〉 0.05). CONCLUSION The test tablets are bioequivalent to the reference tablets through clinical research.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2009年第7期513-517,共5页 Chinese Journal of New Drugs and Clinical Remedies
基金 上海市科委科研计划项目(08411966700)
关键词 比索洛尔 色谱法 高压液相 光谱法 质量 电喷雾电离 药动学 生物等效性 bisoprolol chromatography,high pressure liquid spectrometry,mass,electrospray,ionization pharmacokinetics bioequivalence
  • 引文网络
  • 相关文献

参考文献4

二级参考文献24

  • 1李晓光,赵荣生,翟所迪,陈凤荣,马子静.国产与进口富马酸比索洛尔片剂的人体生物等效性比较[J].中国新药杂志,2005,14(5):602-606. 被引量:5
  • 2张振清,袁淑兰,乔建忠,王淑范,汪伟.高效液相色谱法测定人血浆中比索洛尔浓度[J].药物分析杂志,1996,16(2):78-80. 被引量:7
  • 3黄震华.比索洛尔在心力衰竭治疗中的应用[J].中国新药与临床杂志,2006,25(6):471-474. 被引量:19
  • 4郑东诞,曾群英,王强,许庆,郭象淼.比索洛尔佐治不稳定型心绞痛47例疗效分析[J].新医学,2006,37(7):445-447. 被引量:19
  • 5Fogari R, Zoppi A, Corradi L, et al. β-bloeker effects on plasma lipids during prolonged treament of hypertensive patients with hypereholesteremia[J]. J Cardiovasc Pharmacol,1999,33(4):534 - 539.
  • 6Schnabel P, Maack C, Mies F, et al. Binding properties of betablockers at recombinant betal, beta2 and beta3-ardenoceptors [J]. J Cardiovasc Pharmacol, 2000,36(4) : 466 - 471.
  • 7Smith C,Teitler M. Beta-blocker selectivity at cloned human beta1 and beta2 adrenergic receptors [J]. Cardiovasc Drugs Ther, 1999,13(2) : 123 - 126.
  • 8DUBACH P,MYERS J,BONETYI P,et al.Effects of bisoprolol fumarate on left ventricular size,function,and exercise capacity in patients with heart failure:analysis with magnetic resonance myocardial tagging[J].Am Heart J,2002,143(4):676-683.
  • 9LECHAT P,HULOT JS,MALLET A,et al.Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS Ⅱ Trial[J].Circulation,2001,103(10):1428-1433.
  • 10McGAVIN JK,KEATING GM.Bisoprolol:a review of its use in chronic heart failure[J].Drugs,2002,2(18):2677-2696.

共引文献19

同被引文献9

引证文献1

;
使用帮助 返回顶部